US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer

Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation

Lung cancer is the leading cause of cancer death among men and women

AstraZeneca PLC’s (LON:AZN) lung cancer drug, Tagrisso, has been approved by the US Food and Drug Administration as a first-line treatment.

The approval is for patients whose tumours have certain mutations have epidermal growth factor receptor (EGFR) mutations.

Tagrisso has been used as a second-line treatment in the US since last March, while the pill is still under regulatory review in the EU and Japan for use in the first-line treatment setting, with decisions expected later this year.

“Today's FDA approval of Tagrisso in the 1st-line setting is an exciting milestone for patients and our company,” Astra’s head of oncology Dave Fredrickson.

“Tagrisso delivered unprecedented median progression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading.”

AstraZeneca shares edged 6p higher to £49.70 in early deals on Thursday.

Quick facts: AstraZeneca

Price: 8470 GBX

Market: LSE
Market Cap: £111.15 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Alpha Growth PLC using experienced team to start Alpha Growth and Income...

Alpha Growth PLC (LON: ALGW) CEO Gobind Sahney joined Steve Darling from Proactive to discuss the fund called Alpha Growth and Income fund or AGI. This funds prospective client are family offices, pension funds, and other institutions that still wish to receive some income but also want their...

12 hours, 48 minutes ago

2 min read